TherapeuticsMD (TXMD) Gross Margin (2011 - 2023)

TherapeuticsMD's Gross Margin history runs 13 years deep, the most recent figure standing at 107.04% for Q4 2023.

• Quarterly Gross Margin rose 704.0% year-over-year to 107.04% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 94.69% (down 2400.0% YoY) and the FY2023 annual result came in at 100.0%, up 200.0% from the prior year.
• Gross Margin was 107.04% for Q4 2023 at TherapeuticsMD, up from 100.0% in the prior quarter.
• Across five years, Gross Margin topped out at 2082.45% in Q1 2022 and bottomed at 100.0% in Q3 2023.
• A 5-year average of 185.15% and a median of 81.28% in 2019 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2022 — Gross Margin soared 200604 bps — and 2023, when it plunged 198245 bps.
• TherapeuticsMD's Gross Margin stood at 81.9% in 2019, then retreated by 8 bps to 75.28% in 2020, then declined by 1 bps to 74.64% in 2021, then jumped by 34 bps to 100.0% in 2022, then grew by 7 bps to 107.04% in 2023.
• Business Quant data shows TXMD's Gross Margin at 107.04% in Q4 2023, 100.0% in Q3 2023, and 100.0% in Q2 2023.